SRPT vs. JAZZ, IONS, MRTX, RARE, PTCT, TAK, ALNY, TEVA, GMAB, and RPRX
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of 1.20%. Sarepta Therapeutics' return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
In the previous week, Sarepta Therapeutics had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Sarepta Therapeutics and 8 mentions for Jazz Pharmaceuticals. Sarepta Therapeutics' average media sentiment score of 0.68 beat Jazz Pharmaceuticals' score of 0.65 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
Jazz Pharmaceuticals has higher revenue and earnings than Sarepta Therapeutics. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 330 more outperform votes than Jazz Pharmaceuticals when rated by MarketBeat users. However, 80.56% of users gave Jazz Pharmaceuticals an outperform vote while only 75.40% of users gave Sarepta Therapeutics an outperform vote.
Jazz Pharmaceuticals currently has a consensus price target of $192.75, indicating a potential upside of 83.14%. Sarepta Therapeutics has a consensus price target of $164.00, indicating a potential upside of 26.29%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Sarepta Therapeutics.
Jazz Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats Sarepta Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
